Fatty liver disease is assessed with a combination of medical history, blood tests and imaging. The current term for the common metabolic form is MASLD (metabolic dysfunction-associated steatotic liver disease); older results may call it NAFLD. Clinicians use tests such as FIB-4 to estimate the risk of liver scarring (fibrosis), then may use elastography or another test to refine that estimate. These tests guide care, but a blood result or scan does not by itself reveal every feature of liver disease.
What happens during an evaluation?
An evaluation may begin after imaging shows fat in the liver, liver blood tests remain abnormal, or a person has metabolic risk factors. A clinician reviews alcohol intake, medicines and supplements, other possible causes of liver injury, and health conditions such as diabetes and high blood pressure. The aim is not only to establish whether fat is present, but also to assess the likelihood of fibrosis and decide whether more testing is needed.
As an Amazon Associate I earn from qualifying purchases.
MASLD refers to steatotic liver disease accompanied by at least one cardiometabolic risk factor and without harmful alcohol intake. NAFLD is the older term that may still appear in records. Finding fat on an ultrasound does not establish whether fibrosis is present or how advanced it may be. [AASLD overview]
What can blood tests show?
Routine liver chemistries, including ALT and AST, can help clinicians assess liver injury, but normal or abnormal enzyme levels alone do not reliably stage fibrosis. A commonly used first-step estimate is FIB-4, calculated from age, AST, ALT and platelet count. It is a risk score—not a diagnosis of fatty liver or proof that fibrosis is present or absent.
How clinicians interpret FIB-4
In the AASLD pathway, a score below 1.3 generally supports follow-up in primary care for many adults; a score of 1.3 or higher prompts consideration of a second-stage assessment. For adults older than 65, AASLD uses a higher threshold—above 2.0—to consider that next step. FIB-4 is less accurate in people younger than 35 and should not be used during acute illness. These are pathway thresholds, not stand-alone diagnostic cutoffs; age, health context and other findings matter. [AASLD overview; AASLD 2023 guidance]
What are FibroScan, elastography and ELF?
If FIB-4 is elevated, results are unclear, or clinical suspicion remains high, a clinician may order a second-stage test. The choice depends on the question being asked, availability and the person’s circumstances. The tests are not interchangeable: some estimate liver stiffness or fibrosis risk, while others can estimate liver fat.
| Test | What it assesses | How it is performed | Place in evaluation |
|---|---|---|---|
| Vibration-controlled transient elastography (VCTE), often called FibroScan | Liver stiffness as an indicator of fibrosis risk; its controlled attenuation parameter can estimate steatosis (fat). | Non-invasive imaging-based measurement. | Common second-stage assessment after FIB-4 or when risk remains concerning. |
| Enhanced Liver Fibrosis (ELF) test | Blood markers associated with fibrosis. | Blood test. | Can help refine risk, including as an alternative to elastography in some pathways. |
| MRI-based assessment | Can provide additional information about fat or fibrosis, depending on the method used. | Imaging. | May be considered when other non-invasive results are indeterminate or disagree. |
Elastography and ELF help estimate risk; they do not directly show all microscopic features of steatohepatitis, such as ballooning and lobular inflammation. European guidance supports a stepwise approach: start with a blood-based score such as FIB-4, then consider elastography if fibrosis remains a concern or the person is in a high-risk group; ELF may be another option. [EASL-EASD-EASO 2024 guideline]
Free tools Windows power users keep installed
One-click scans. No signup required.
When is a liver biopsy considered?
Biopsy is not routine for everyone with MASLD. It may be considered when a definite diagnosis of steatohepatitis is needed, another cause of liver disease must be investigated, non-invasive results leave important uncertainty, or clinical suspicion remains high. A biopsy examines a small sample of liver tissue and can assess microscopic changes that non-invasive tests cannot fully characterize.
Rank #3
The EASL-EASD-EASO 2024 guideline states: “In most cases, liver biopsy is not required for clinical management of individuals with MASLD; however, liver biopsy is still required for the definite diagnosis of steatohepatitis and can help to rule out alternative causes of liver disease.” [EASL-EASD-EASO 2024 guideline]
How often is MASLD monitored?
Follow-up timing depends on fibrosis risk, prior results, age, diabetes and other metabolic risks. In its 2023 guidance, AASLD describes reassessing FIB-4 every 1–2 years for people with prediabetes or type 2 diabetes, or at least two metabolic risk factors. For people without prediabetes or type 2 diabetes and with fewer metabolic risks, it describes reassessment every 2–3 years. These intervals belong to that pathway; a clinician may choose a different plan based on the individual picture. [AASLD 2023 guidance]
The American Gastroenterological Association (AGA) pathway uses its own thresholds and follow-up approach. For example, it identifies FIB-4 below 1.3—or below 2.0 for people aged 65 or older—as generally supporting primary-care management in that pathway. It also describes VCTE stiffness below 8 kPa or ELF below 9.2 as generally low risk. These figures are not universal cutoffs and should be interpreted in their pathway and clinical context. [AGA clinical care pathway]
What should follow-up cover beyond the liver?
Monitoring should include the conditions that commonly accompany MASLD, rather than focusing only on liver enzymes or scan results. European guidance recommends assessing associated health conditions at diagnosis and during regular follow-up, including type 2 diabetes, abnormal blood lipids, high blood pressure, kidney disease, sleep apnoea and cardiovascular risk. The clinician can use these findings alongside liver assessments to plan appropriate care. [EASL-EASD-EASO 2024 guideline]
Quick Recap
Best Value
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
